Abstract
Understanding of the genetic and epigenetic factors contributing to the pathogenesis of leukemia has a high impact on blood cancer therapy. In Chap. 1 we review the hematopoiesis process—formation of blood cells from fetus development throughout adulthood. The number of genetic and epigenetic alterations that arise in normal cells during the many years of life could cause blood cancer. The types of leukemia, pathogenesis of AML, and genetic and epigenetic landscape of AML are presented in the chapter. Also standard and new strategies of AML treatment to improve remission induction are described.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Allis CD, Jenuwein T (2016) The molecular hallmarks of epigenetic control. Nat Rev Genet 17(8):487–500. https://doi.org/10.1038/nrg.2016.59
Antar AI, Otrock ZK, Jabbour E, Mohty M, Bazarbachi A (2020) FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions. Leukemia. https://doi.org/10.1038/s41375-019-0694-3
Asada S, Fujino T, Goyama S, Kitamura T (2019) The role of ASXL1 in hematopoiesis and myeloid malignancies. Cell Mol Life Sci 76:2511–2523
Bacher U, Haferlach C, Schnittger S, Kohlmann A, Kern W, Haferlach T (2010) Mutations of the TET2 and CBL genes: novel molecular markers in myeloid malignancies. Ann Hematol 89(7):643–652. https://doi.org/10.1007/s00277-010-0920-6
Bannister AJ, Kouzarides T (2011) Regulation of chromatin by histone modifications. Cell Res 21(3):381–395. https://doi.org/10.1038/cr.2011.22
Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DAG, Gralnick HR, Sultan C (1976) Proposals for the classification of the acute leukaemias French-American-British (FAB) co-operative group. Br J Haematol 33(4):451–458
Bernstein BE, Meissner A, Lander ES (2007) The mammalian epigenome. Cell 128(4):669–681. https://doi.org/10.1016/j.cell.2007.01.033
Betz BL, Hess JL (2010) Acute myeloid leukemia diagnosis in the 21st century. Arch Pathol Lab Med 134(10):1427–1433
Bewersdorf JP, Shallis R, Stahl M, Zeidan AM (2019) Epigenetic therapy combinations in acute myeloid leukemia: what are the options? Ther Adv Hematol 10. https://doi.org/10.1177/2040620718816698
Bhattacharya P, Patel TN (2018) Microsatellite instability and promoter hypermethylation of DNA repair genes in hematologic malignancies: a forthcoming direction toward diagnostics. Hematology 23(2):77–82. https://doi.org/10.1080/10245332.2017.1354428
Bloomfield CD, Brunning RD (1985) FAB M7: acute megakaryoblastic leukemia–beyond morphology. Ann Intern Med 103(3):450–452
Borutinskaite VV, Savickiene J, Navakauskiene R (2008) Apoptotic effects of the novel histone deacetylase inhibitor BML-210 on HeLa cells. Biologija (3):217–220
Bugler J, Kinstrie R, Scott MT, Vetrie D (2019) Epigenetic reprogramming and emerging epigenetic therapies in CML. Front Cell Dev Biol 7:136
Dash A, Gilliland D (2001) Molecular genetics of acute myeloid leukaemia. Best Pract Res Clin Haematol 14(1):49–64. https://doi.org/10.1053/beha.2000.0115
Dawson MA, Kouzarides T (2012) Cancer epigenetics: From mechanism to therapy. Cell 150(1):12–27. https://doi.org/10.1016/j.cell.2012.06.013
Dawson MA, Kouzarides T, Huntly BJP (2012) Targeting epigenetic readers in cancer. N Engl J Med 367(7):647–657. https://doi.org/10.1056/NEJMra1112635
De Kouchkovsky I, Abdul-Hay M (2016) Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J 6. https://doi.org/10.1038/bcj.2016.50
Dhall A, Zee BM, Yan F, Blanco MA (2019) Intersection of epigenetic and metabolic regulation of histone modifications in acute myeloid leukemia. Front Oncol 9. https://doi.org/10.3389/fonc.2019.00432
Dombret H (2011) Gene mutation and AML pathogenesis. Blood 118(20):5366–5367. https://doi.org/10.1182/blood-2011-09-379081
Falini B, Tiacci E, Martelli MP, Ascani S, Pileri SA (2010) New classification of acute myeloid leukemia and precursor-related neoplasms: changes and unsolved issues. Discov Med 10(53):281–292
Feinberg AP, Ohlsson R, Henikoff S (2006) The epigenetic progenitor origin of human cancer. Nat Rev Genet 7(1):21–33. https://doi.org/10.1038/nrg1748
Fiedler K, Brunner C (2012) The role of transcription factors in the guidance of granulopoiesis. Am J Blood Res 2(1):57–65
Furuya K, Ikura M, Ikura T (2019) Epigenetic interplays between DNA demethylation and histone methylation for protecting oncogenesis. J Biochem 165(4):297–299. https://doi.org/10.1093/jb/mvy124
Goldman SL, Hassan C, Khunte M, Soldatenko A, Jong Y, Afshinnekoo E, Mason CE (2019) Epigenetic modifications in acute myeloid leukemia: Prognosis, treatment, and heterogeneity. Front Genet 10. https://doi.org/10.3389/fgene.2019.00133
Grigoropoulos NF, Petter R, Van’t Veer MB, Scott MA, Follows GA (2013a) Leukaemia update. part 1: diagnosis and management. BMJ-Br Med J 346. https://doi.org/10.1136/bmj.f1660
Grigoropoulos NF, Petter R, Van’t Veer MB, Scott MA, Follows GA (2013b) Leukaemia update. part 2: managing patients with leukaemia in the community. BMJ-Br Med J 346. https://doi.org/10.1136/bmj.f1932
He L, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, Zelent A, Pandolfi P (1998) Distinct interactions of PML-RAR alpha and PLZF-RAR alpha with co-repressors determine differential responses to RA in APL. Nat Genet 18(2):126–135. https://doi.org/10.1038/ng0298-126
Horton SJ, Huntly BJP (2012) Recent advances in acute myeloid leukemia stem cell biology. Haematologica Hematol J 97(7):966–974. https://doi.org/10.3324/haematol.2011.054734
Hussain L, Maimaitiyiming Y, Islam K, Naranmandura H (2019) Acute promyelocytic leukemia and variant fusion proteins: PLZF-RAR alpha fusion protein at a glance. Semin Oncol 46(2):133–144. https://doi.org/10.1053/j.seminoncol.2019.04.004
Kiyoi H, Kawashima N, Ishikawa Y (2020) FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development. Cancer Sci. https://doi.org/10.1111/cas.14274
Kohlmann A, Bullinger L, Thiede C, Schaich M, Schnittger S, Doehner K, Dugas M, Klein HU, Doehner H, Ehninger G, Haferlach T (2010) Gene expression profiling in AML with normal karyotype can predict mutations for molecular markers and allows novel insights into perturbed biological pathways. Leukemia 24(6):1216–1220. https://doi.org/10.1038/leu.2010.73
Kouzarides T (2007) Snapshot: Histone-modifying enzymes. Cell 131(4):802–e1. https://doi.org/10.1016/j.cell.2007.11.005
Kramer A, Challen GA (2017) The epigenetic basis of hematopoietic stem cell aging. Semin Hematol 54(1):19–24. https://doi.org/10.1053/j.seminhematol.2016.10.006
Kreitz J, Schoenfeld C, Seibert M, Stolp V, Alshamleh I, Oellerich T, Steffen B, Schwalbe H, Schnuetgen F, Kurrle N, Serve H (2019) Metabolic plasticity of acute myeloid leukemia. Cells 8(8). https://doi.org/10.3390/cells8080805
Lagunas-Rangel FA, Chavez-Valencia V, Gomez-Guijosa MA, Cortes-Penagos C (2017) Acute myeloid leukemia-genetic alterations and their clinical prognosis. Int J Hematol Oncol Stem Cell Res 11(4):328–339
Lee EJ, Pollak A, Leavitt RD, Testa JR, Schiffer CA (1987) Minimally differentiated acute nonlymphocytic leukemia: a distinct entity. Blood 70(5):1400–1406
Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, Kandoth C, Payton JE, Baty J, Welch J, Harris CC, Lichti CF, Townsend RR, Fulton RS, Dooling DJ, Koboldt DC, Schmidt H, Zhang Q, Osborne JR, Lin L, O’Laughlin M, McMichael JF, Delehaunty KD, McGrath SD, Fulton LA, Magrini VJ, Vickery TL, Hundal J, Cook LL, Conyers JJ, Swift GW, Reed JP, Alldredge PA, Wylie T, Walker J, Kalicki J, Watson MA, Heath S, Shannon WD, Varghese N, Nagarajan R, Westervelt P, Tomasson MH, Link DC, Graubert TA, DiPersio JF, Mardis ER, Wilson RK (2010) DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363(25):2424–2433. https://doi.org/10.1056/NEJMoa1005143
Maher M, Diesch J, Casquero R, Buschbeck M (2018) Epigenetic-transcriptional regulation of fatty acid metabolism and its alterations in leukaemia. Front Genet 9. https://doi.org/10.3389/fgene.2018.00405
Mansouri L, Wierzbinska JA, Plass C, Rosenquist R (2018) Epigenetic deregulation in chronic lymphocytic leukemia: clinical and biological impact. In: Seminars in Cancer Biology, vol 51. Elsevier, New York, pp 1–11
Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K, Koboldt DC, Fulton RS, Delehaunty KD, McGrath SD, Fulton LA, Locke DP, Magrini VJ, Abbott RM, Vickery TL, Reed JS, Robinson JS, Wylie T, Smith SM, Carmichael L, Eldred JM, Harris CC, Walker J, Peck JB, Du F, Dukes AF, Sanderson GE, Brummett AM, Clark E, McMichael JF, Meyer RJ, Schindler JK, Pohl CS, Wallis JW, Shi X, Lin L, Schmidt H, Tang Y, Haipek C, Wiechert ME, Ivy JV, Kalicki J, Elliott G, Ries RE, Payton JE, Westervelt P, Tomasson MH, Watson MA, Baty J, Heath S, Shannon WD, Nagarajan R, Link DC, Walter MJ, Graubert TA, DiPersio JF, Wilson RK, Ley TJ (2009) Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361(11):1058–1066. https://doi.org/10.1056/NEJMoa0903840
Mesuraca M, Amodio N, Chiarella E, Scicchitano S, Aloisio A, Codispoti B, Lucchino V, Montalcini Y, Bond HM, Morrone G (2018) Turning stem cells bad: Generation of clinically relevant models of human acute myeloid leukemia through gene delivery- or genome editing-based approaches. Molecules 23(8). https://doi.org/10.3390/molecules23082060
Monaghan L, Massett ME, Bunschoten RP, Hoose A, Pirvan PA, Liskamp RMJ, Jorgensen HG, Huang X (2019) The emerging role of h3k9me3 as a potential therapeutic target in acute myeloid leukemia. Front Oncol 9. https://doi.org/10.3389/fonc.2019.00705
Morrison SJ, Scadden DT (2014) The bone marrow niche for haematopoietic stem cells. Nature 505(7483):327–334. https://doi.org/10.1038/nature12984
Network TCGAR (2013) Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 368(22):2059–2074
Nordlund J, Syvaenen AC (2018) Epigenetics in pediatric acute lymphoblastic leukemia. Semin Cancer Biol 51:129–138
Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N et al (2016) Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med 374(23):2209–2221
Patnaik MM, Tefferi A (2020) Chronic myelomonocytic leukemia: 2020 update on diagnosis, risk stratification and management. Am J Hematol 95(1):97–115
Pelosi E, Castelli G, Testa U (2015) Targeting LSCs through membrane antigens selectively or preferentially expressed on these cells. Blood Cells Mol Dis 55(4):336–346. https://doi.org/10.1016/j.bcmd.2015.07.015
Pradhan S, Chin HG, Esteve PO, Jacobsen SE (2009) Set7/9 mediated methylation of non-histone proteins in mammalian cells. Epigenetics 4(6):282–285
Raval A, Byrd JC, Plass C (2006) Epigenetics in chronic lymphocytic leukemia. Semin Oncol 33:157–166
Rego EM, Pandolfi PP (2002) Reciprocal products of chromosomal translocations in human cancer pathogenesis: key players or innocent bystanders? Trends Mol Med 8(8):396–405. https://doi.org/10.1016/S1471-4914(02)02384-5
Rodriguez-Paredes M, Esteller M (2011) A combined epigenetic therapy equals the efficacy of conventional chemotherapy in refractory advanced non-small cell lung cancer. Cancer Discov 1(7):557–559. https://doi.org/10.1158/2159-8290.CD-11-0271
Sawyers CL, Denny CT, Witte ON (1991) Leukemia and the disruption of normal hematopoiesis. Cell 64(2):337–350. https://doi.org/10.1016/0092-8674(91)90643-D
Scaglioni PP, Pandolfi PP (2007) The theory of APL revisited. In: Pandolfi P, Vogt P (eds) Acute promyelocytic leukemia: molecular genetics, mouse models and targeted therapy, Current topics in microbiology and immunology, vol 313, pp 85–100
Seiter K (2003) Diagnosis and management of core-binding factor leukemias. Curr Hematol Rep 2(1):78–85
Seiter K (2013) Myelodysplasia: New approaches. Curr Treat Options Oncol 14(2):156–169. https://doi.org/10.1007/s11864-013-0224-x
Shen Y, Zhu YM, Fan X, Shi JY, Wang QR, Yan XJ, Gu ZH, Wang YY, Chen B, Jiang CL, Yan H, Chen FF, Chen HM, Chen Z, Jin J, Chen SJ (2011) Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia. Blood 118(20):5593–5603. https://doi.org/10.1182/blood-2011-03-343988
Stirewalt DL, Meshinchi S (2010) Receptor tyrosine kinase alterations in AML - biology and therapy. Cancer Treat Res 145:85–108
Stirewalt DL, Radich JP (2003) The role of flt3 in haematopoietic malignancies. Nat Rev Cancer 3(9):650–U1. https://doi.org/10.1038/nrc1169
Stirewalt DL, Meshinchi S, Radich JP (2003) Molecular targets in acute myelogenous leukemia. Blood Rev 17(1):15–23. https://doi.org/10.1016/S0268-960X(02)00057-7
Suela J, Alvarez S, Cigudosa JC (2007) DNA profiling by arrayCGH in acute myeloid leukemia and myelodysplastic syndromes. Cytogenet Genome Res 118(2–4):304–309. https://doi.org/10.1159/000108314
Vardiman JW, Harris NL, Brunning RD (2002) The World Health Organization (who) classification of the myeloid neoplasms. Blood 100(7):2292–2302
Walter MJ, Payton JE, Ries RE, Shannon WD, Deshmukh H, Zhao Y, Baty J, Heath S, Westervelt P, Watson MA, Tomasson MH, Nagarajan R, O’Gara BP, Bloomfield CD, Mrozek K, Selzer RR, Richmond TA, Kitzman J, Geoghegan J, Eis PS, Maupin R, Fulton RS, McLellan M, Wilson RK, Mardis ER, Link DC, Graubert TA, DiPersio JF, Ley TJ (2009) Acquired copy number alterations in adult acute myeloid leukemia genomes. Proc Natl Acad Sci U S A 106(31):12950–12955. https://doi.org/10.1073/pnas.0903091106
Wang X, Huang S, Chen JL (2017) Understanding of leukemic stem cells and their clinical implications. Mol Cancer 16. https://doi.org/10.1186/s12943-016-0574-7
Wilson A, Oser GM, Jaworski M, Blanco-Bose WE, Laurenti E, Adolphe C, Essers MA, Macdonald HR, Trumpp A (2007) Dormant and self-renewing hematopoietic stem cells and their niches. In: Kanz L, Weisel K, Dick J, Fibbe W (eds) Hematopoietic stem cells VI, Annals of the New York Academy of Sciences, vol 1106, pp 64–75. https://doi.org/10.1196/annals.1392.021. 6th Biennial International Symposium and Workshop on Hematopoietic Stem Cells, Univ Tubingen, Tubingen, 14–16, 2006
Yang X, Wong MPM, Ng RK (2019) Aberrant dna methylation in acute myeloid leukemia and its clinical implications. Int J Mol Sci 20(18). https://doi.org/10.3390/ijms20184576
Yasuda T, Ueno T, Fukumura K, Yamato A, Ando M, Yamaguchi H, Soda M, Kawazu M, Sai E, Yamashita Y, Murata M, Kiyoi H, Naoe T, Mano H (2014) Leukemic evolution of donor-derived cells harboring IDH2 and DNMT3A mutations after allogeneic stem cell transplantation. Leukemia 28(2):426–428. https://doi.org/10.1038/leu.2013.278
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Navakauskienė, R., Navakauskas, D., Borutinskaitė, V., Matuzevičius, D. (2021). Epigenetic and Genetic Alterations in Leukemia. In: Epigenetics and Proteomics of Leukemia. Springer, Cham. https://doi.org/10.1007/978-3-030-68708-3_1
Download citation
DOI: https://doi.org/10.1007/978-3-030-68708-3_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-68707-6
Online ISBN: 978-3-030-68708-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)